Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Shanghai Fosun Pharmaceutical (Group) Co Debt-to-EBITDA?
Shanghai Fosun Pharmaceutical (Group) CoSFOSF 77 Debt-to-EBITDA is 5.98 as of Mar. 2026, which is 60% above its 10-year median of 3.74. GuruFocus rates SFOSF with a GF Score™ of 77/100 and a GF Value™ of $2.79 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 690 Drug Manufacturers companies, Shanghai Fosun Pharmaceutical (Group) Co ranks worse than 85.8% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Shanghai Fosun Pharmaceutical (Group) Co Debt-to-EBITDA Related Terms
Shanghai Fosun Pharmaceutical (Group) Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Fosun Pharmaceutical (Group) Co Debt-to-EBITDA Chart
Shanghai Fosun Pharmaceutical (Group) Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fosun Pharmaceutical (Group) Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Fosun Pharmaceutical (Group) Co Debt-to-EBITDA vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) has a Debt-to-EBITDA of 5.98 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Fosun Pharmaceutical (Group) Co. This is 60% above median its historical median of 3.74. Over the past decade, Shanghai Fosun Pharmaceutical (Group) Co's Debt-to-EBITDA has ranged from 2.34 to 6.22. According to the industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #592 out of 690 companies in the Drug Manufacturers industry, placing it in the top 85.8%.
Is Shanghai Fosun Pharmaceutical (Group) Co's Debt-to-EBITDA too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Debt-to-EBITDA of 5.98 is 60% above median its 10-year median of 3.74. Over the past 10 years, this metric has ranged from a low of 2.34 to a high of 6.22. The Drug Manufacturers industry median Debt-to-EBITDA is 1.67. Shanghai Fosun Pharmaceutical (Group) Co's value of 5.98 is 258.1% above this industry median. Based on the distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #592 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shanghai Fosun Pharmaceutical (Group) Co ranks #592 out of 690 companies for Debt-to-EBITDA. This places Shanghai Fosun Pharmaceutical (Group) Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.67. Shanghai Fosun Pharmaceutical (Group) Co's value of 5.98 is 258.1% above this benchmark. Historically, Shanghai Fosun Pharmaceutical (Group) Co's own Debt-to-EBITDA has ranged from 2.34 to 6.22 over the past decade. While the company's 10-year median is 3.74 vs. the industry median of 1.67, Shanghai Fosun Pharmaceutical (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Fosun Pharmaceutical (Group) Co's current Debt-to-EBITDA of 5.98 is 258.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Shanghai Fosun Pharmaceutical (Group) Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Fosun Pharmaceutical (Group) Co's current Debt-to-EBITDA is 5.98, which is 60% above median its own 10-year median of 3.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.79, compared to a current price of $2.20 — trading 21.1% below its estimated fair value. The current Debt-to-EBITDA is 5.98, which is 60% above median its 10-year median of 3.74 and 258.1% above the Drug Manufacturers industry median of 1.67. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (SFOSF), the current Debt-to-EBITDA is 5.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued.
The current stock price of $2.20 is trading 21.1% below its estimated GF Value™ of $2.79.
GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Modestly Undervalued.
Key valuation signals for SFOSF:
Debt-to-EBITDA: 5.98 (60% above median its 10-year median of 3.74)
GF Value™: $2.79 vs. price of $2.20 (21.1% below fair value)
Industry Position: 258.1% above the Drug Manufacturers median (#592 of 690)
No single metric tells the full story. See the SFOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Fosun Pharmaceutical (Group) Co Business Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
77GF Score
Get the complete analysis for SFOSF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SFOSF has been successfully added to your 
